AAC $9.95 ACHR $3.28 +0.15% ▲ AERO $16.20 -1.25% ▼ AIN $65.44 +0.06% ▲ AIR $104.31 -1.13% ▼ AM $20.20 -0.37% ▼ AMP $501.17 -0.18% ▼ AMTM $21.09 +0.81% ▲ APH $77.06 +1.25% ▲ ASB $29.85 -1.35% ▼ ATI $180.41 -0.25% ▼ ATRO $59.01 +0.23% ▲ AVAV $99.90 -2.54% ▼ AVNW $16.74 +1.70% ▲ AXON $313.02 +3.61% ▲ BAB $25.67 +0.18% ▲ BAH $82.82 -1.46% ▼ BBAI $1.76 -0.56% ▼ BDL $52.10 -2.25% ▼ BELFB $225.53 -0.05% ▼ BHE $62.51 +0.77% ▲ BKSY $19.59 -4.81% ▼ BWXT $115.82 -2.29% ▼ CACI $606.43 -0.47% ▼ CAE $27.32 -1.01% ▼ CDRE $31.03 -2.73% ▼ CICN $0.00 CMTL $1.08 -1.95% ▼ CNC $64.99 -4.43% ▼ CODA $7.67 -3.76% ▼ AAC $9.95 ACHR $3.28 +0.15% ▲ AERO $16.20 -1.25% ▼ AIN $65.44 +0.06% ▲ AIR $104.31 -1.13% ▼ AM $20.20 -0.37% ▼ AMP $501.17 -0.18% ▼ AMTM $21.09 +0.81% ▲ APH $77.06 +1.25% ▲ ASB $29.85 -1.35% ▼ ATI $180.41 -0.25% ▼ ATRO $59.01 +0.23% ▲ AVAV $99.90 -2.54% ▼ AVNW $16.74 +1.70% ▲ AXON $313.02 +3.61% ▲ BAB $25.67 +0.18% ▲ BAH $82.82 -1.46% ▼ BBAI $1.76 -0.56% ▼ BDL $52.10 -2.25% ▼ BELFB $225.53 -0.05% ▼ BHE $62.51 +0.77% ▲ BKSY $19.59 -4.81% ▼ BWXT $115.82 -2.29% ▼ CACI $606.43 -0.47% ▼ CAE $27.32 -1.01% ▼ CDRE $31.03 -2.73% ▼ CICN $0.00 CMTL $1.08 -1.95% ▼ CNC $64.99 -4.43% ▼ CODA $7.67 -3.76% ▼

‘If we save one veteran’s life, it’s worth it’: VA faces questions over psychedelic treatments

November 19, 2026 · by DPW Pipeline

The Department of Veterans Affairs estimates roughly 180,000 veterans might qualify for emerging psychedelic-assisted mental health treatments under preliminary screening criteria, but a senior official has warned that reaching a four-digit patient count in the first year could prove challenging.

The potential gap between eligibility and treatment capacity drew scrutiny Wednesday during a House Veterans’ Affairs subcommittee hearing, where lawmakers questioned whether the VA has enough trained clinicians, funding and facilities to deliver the treatments to veterans with post-traumatic stress disorder and severe depression.

“If we save one veteran’s life next year from these treatments, it’s worth it,” Andrew Gradison, a senior adviser to the Veterans Health Administration, told lawmakers.

The VA has identified 10 facilities to support its initial rollout, including locations designated for clinical implementation and clinician training, but has not publicly disclosed the full list. Officials also acknowledged that the department’s fiscal 2027 budget included no dedicated funding request for implementing the treatments, although they maintained that existing resources are sufficient.

Rep. Maggie Goodlander, D-N.H., pressed Gradison on how the department would determine which veterans receive treatment first if demand far exceeds available appointments.

“Who goes first, and who decides?” Goodlander asked. “Is there going to be a role for priority, or does it depend on whether you live near one of the 10 sites?”

Gradison said decisions would be guided by medical ethics, clinical eligibility and patient safety, with treatments initially administered by the department’s most experienced clinicians.

The 180,000 figure is based on screening criteria used in existing research, not confirmed eligibility for an approved treatment. Actual eligibility will depend on which therapies, if any, receive Food and Drug Administration approval and the restrictions accompanying that approval. Gradison’s earlier assessment, discussed at an October healthcare forum, was not a formal treatment capacity projection, and he did not establish a firm first-year capacity during Wednesday’s hearing.

VA officials said approximately 2.1 million veterans receiving VA healthcare have diagnoses involving PTSD, major depressive disorder or treatment-resistant depression. The agency was conducting 21 active psychedelic-treatment studies as of September, including research involving MDMA and psilocybin.

VA research protocols include preparation, supervised dosing sessions lasting six to eight hours, and follow-up treatment, creating substantial demands on clinical staff.

Lawmakers questioned whether the department could sustain that workload amid existing staffing pressures. A September VA inspector general report found that 58% of reporting VA facilities identified severe shortages of psychologists, while federal workforce data showed declines in the number of VA physicians, psychologists and social workers.

Dr. Ilse Wiechers, a senior Veterans Health Administration official, said the VA continues recruiting mental health professionals and is evaluating staffing needs at its initial facilities.

Officials also acknowledged that geographic access will be limited during the first phase. The department plans to expand beyond its initial facilities as clinicians receive training and is developing standards for referring veterans to community providers.

The department is also preparing for regulatory hurdles beyond FDA approval. Psychedelic compounds currently classified as Schedule I controlled substances would require additional federal and potentially state regulatory action before routine clinical use.

Rep. Morgan Luttrell, R-Texas, a longtime advocate of psychedelic treatments for veterans, urged officials to proceed carefully while emphasizing the consequences of failure.

“If you mess up this much, this goes away forever,” Luttrell said.

Gradison agreed to provide Congress with a staffing plan within 30 days, including the number of clinicians needed, where those employees would come from and the projected costs. He separately committed to providing lawmakers with the list of 10 facilities selected for the initial rollout.

Source: www.armytimes.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.